Search research articles
Contact Us
Filters
Showing results (281-290 of 305) with videos related to
Page
of 31
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) CT/PET
A Gennari, E Brain, A De Censi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2014
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L De Mattos-Arruda, B Weigelt, J Cortes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 3, 2018
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L De Mattos-Arruda, B Weigelt, J Cortes, et al.
Leukemia
|
November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
E Jabbour, P D le Coutre, J Cortes, et al.
Bone Marrow Transplantation
|
October 12, 2011
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
H J Khoury, M Kukreja, J M Goldman, et al.
Cell Reports
|
November 12, 2023
Skeletal muscle TFEB signaling promotes central nervous system function and reduces neuroinflammation during aging and neurodegenerative disease
Ian Matthews, Allison Birnbaum, Anastasia Gromova, et al.
Leukemia
|
August 30, 2008
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
J Cortes, D-W Kim, E Raffoux, et al.
Leukemia
|
June 13, 2008
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
E J Feldman, J Cortes, D J DeAngelo, et al.
Leukemia
|
June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
F J Giles, E Abruzzese, G Rosti, et al.
Inflammatory Bowel Diseases
|
May 17, 2019
Challenges in IBD Research: Preclinical Human IBD Mechanisms
Theresa T Pizarro, Thaddeus S Stappenbeck, Florian Rieder, et al.
Page
of 31
Search research articles
Search
Showing results (281-290 of 305) with videos related to
Sort By:
Page
of 31
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) CT/PET
A Gennari, E Brain, A De Censi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2014
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L De Mattos-Arruda, B Weigelt, J Cortes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 3, 2018
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle
L De Mattos-Arruda, B Weigelt, J Cortes, et al.
Leukemia
|
November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
E Jabbour, P D le Coutre, J Cortes, et al.
Bone Marrow Transplantation
|
October 12, 2011
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
H J Khoury, M Kukreja, J M Goldman, et al.
Cell Reports
|
November 12, 2023
Skeletal muscle TFEB signaling promotes central nervous system function and reduces neuroinflammation during aging and neurodegenerative disease
Ian Matthews, Allison Birnbaum, Anastasia Gromova, et al.
Leukemia
|
August 30, 2008
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
J Cortes, D-W Kim, E Raffoux, et al.
Leukemia
|
June 13, 2008
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia
E J Feldman, J Cortes, D J DeAngelo, et al.
Leukemia
|
June 4, 2010
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
F J Giles, E Abruzzese, G Rosti, et al.
Inflammatory Bowel Diseases
|
May 17, 2019
Challenges in IBD Research: Preclinical Human IBD Mechanisms
Theresa T Pizarro, Thaddeus S Stappenbeck, Florian Rieder, et al.
Page
of 31